The Technical Analyst
Diffusion Pharmaceuticals [DFFN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Diffusion Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
10.28% $4.40
America/New_York / 16 aug 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.98 mill |
| EPS: | -7.11 |
| P/E: | -0.619 |
| Earnings Date: | Nov 12, 2023 |
| SharesOutstanding: | 2.04 mill |
| Avg Daily Volume: | 0.0478 mill |
| RATING 2023-10-09 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.619 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.619 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 6.39 - 6.81 ( +/- 3.24%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-20 | Tanner John William | Buy | 32 000 | Stock Option (Right to Buy) |
| 2023-11-09 | Gregoire Sylvie | Sell | 10 000 | Common Stock |
| 2023-11-09 | Alam John J | Sell | 12 500 | Common Stock |
| 2023-09-15 | Cobuzzi Robert Joseph Jr. | Buy | 16 000 | Stock Option (Right to Buy) |
| 2023-09-15 | Tanner John William | Buy | 16 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 44.87 |
| Last 93 transactions |
| Buy: 1 964 449 | Sell: 147 821 |
Forecast:
01:40 - $4.53
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.40 (10.28% ) |
| Volume | 0.349 mill |
| Avg. Vol. | 0.0478 mill |
| % of Avg. Vol | 730.87 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DFFN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DFFN
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Latest Press Releases
2023-08-16 13:58:00 - Press Release
Cervomed Announces Completion Of Merger With Eip Pharma
Shares of cervomed to commence trading on nasdaq under new ticker symbol "crvo" on august 17, 2023 cervomed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with lewy bodies and other degenerative diseases of the brain cervomed has a cash runway through phase 2b clinical data which is expected during 2h 2024 boston , aug. 16, 2023 /prnewswire/ -- cervomed inc. (formerly known as diffusion pharmaceuticals inc.) (nasdaq: crvo), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced the closing of its previously announced merger with eip pharma inc. the combined company will operate under the name cervomed inc...
2023-08-15 16:01:00 - Press Release
Diffusion Pharmaceuticals Stockholders Approve Merger With Eip Pharma
Approximately 71% of stockholders voted in favor of the transaction diffusion announces 1-for-1.5 reverse stock split merger on track to close on august 16, 2023
2023-04-03 14:13:00 - Press Release
Shareholder Investigation: Halper Sadeh Llc Investigates Hska, Lsi, Exr, Dffn
New york , april 3, 2023 /prnewswire/ -- halper sadeh llc, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: heska corporation (nasdaq: hska)'s sale to mars, incorporated for $120.00 per share. if you are a heska shareholder, click here to learn more about your rights and options.
2023-03-31 20:01:00 - Press Release
Diffusion Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Diffusion Pharmaceuticals Inc. - Dffn
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of diffusion pharmaceuticals inc. (the “company”) (nasdaqcm: dffn) with eip pharma inc. pursuant to which diffusion shareholders will end up owning 22.75% of the total number of outstanding shares of the combined company, subject to adjustment. ksf is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the company. if you believe that this transaction undervalues the company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call ksf managing partner lewis s...
2023-03-30 10:42:00 - Press Release
Dffn Stock Alert: Halper Sadeh Llc Is Investigating Whether The Merger Of Diffusion Pharmaceuticals Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the merger of diffusion pharmaceuticals inc. (nasdaq: dffn) and eip pharma inc. is fair to diffusion shareholders. halper sadeh encourages diffusion shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether diffusion and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for diffusion shareholders; and (2) disclose all material information necessary for diffusion shareholders to adequately assess and value the merger consideration...
Latest News
2022-05-17 07:30:00 - GlobeNewsWire
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company's President and Chief Executive Officer, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.
2022-04-19 18:01:02 - Benzinga
5 Stocks Halted In Tuesday's Session
A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to the markets.
2022-04-18 20:28:06 - Pulse2
Diffusion Pharmaceuticals (DFFN) Stock: 1-For-50 Reverse Stock Split Announced
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) announced it will effect a 1-for-50 reverse stock split of its common stock. These are the details.
2022-04-18 10:52:04 - Benzinga
Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) will effect a 1-for-50 reverse stock split of its common stock. The reverse stock split is expected to become effective and commence trading on a post-split basis at the market's opening on April 19.
2022-04-18 09:48:03 - Benzinga
Why Diffusion Pharmaceuticals Shares Are Falling
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares are trading lower by 20.83% at $0.21 after the company announced a 1-for-50 reverse stock split. Diffusion Pharmaceuticals says the reverse stock split is expected to become effective at 5:59 p.m.
2021-12-20 07:02:00 - GlobeNewsWire
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P.
CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three events are scheduled alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.
2021-12-01 13:51:42 - Pulse2
Diffusion Pharmaceuticals (DFFN) Stock: Why The Price Increased Today
The stock price of Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) increased by over 5% during intraday trading today. This is why it happened.
2021-11-29 13:14:30 - PennyStocks
Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility
Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-10-14 09:25:31 - InvestorPlace
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appeared first on InvestorPlace.
2021-09-09 07:32:00 - GlobeNewsWire
Diffusion Pharmaceuticals Issues Letter to Shareholders
CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders. The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022.